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ABSTRACT  
 
Purpose. Prognosis of early beast cancer is heterogeneous. Today, no histo-clinical or 
biological factor predictive for clinical outcome after adjuvant anthracycline-based 
chemotherapy (CT) has been validated and introduced in routine use. Using DNA 
microarrays, we searched for a gene expression signature associated with metastatic 
relapse after adjuvant anthracycline-based CT without taxane. 
Methods. We profiled a multicentric series of 595 breast cancers including 498 treated 
with such adjuvant CT. The identification of the prognostic signature was done using a 
metagene-based supervised approach in a learning set of 323 patients. The signature 
was then tested on an independent validation set comprised of 175 similarly treated 
patients, 128 of them from the PACS01 prospective clinical trial. 
Results. We identified a 3-metagene predictor of metastatic relapse in the learning set, 
and confirmed its independent prognostic impact in the validation set. In multivariate 
analysis, the predictor outperformed the individual current prognostic factors, as well as 
the Nottingham Prognostic Index-based classifier, both in the learning and the validation 
sets, and added independent prognostic information. Among the patients treated with 
adjuvant anthracycline-based CT, with a median follow-up of 68 months, the 5-year 
metastasis-free survival was 82% in the “good-prognosis” group and 56% in the “poor-
prognosis” group.  
Conclusion. Our predictor refines the prediction of metastasis-free survival after 
adjuvant anthracycline-based CT and might help tailoring adjuvant CT regimens.  
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LIST OF ABBREVIATIONS 
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receptor; PR: progesterone receptor; FEC: 5-fluoro-uracile + epirubicine + 
cyclophosphamide; PCR: polymerase chain reaction; MFS: metastasis-free survival; 
HR: hazard ratio. 
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INTRODUCTION  
 
Survival of early breast cancer patients has increased in relation with screening 
programs and adjuvant hormone therapy (HT), chemotherapy (CT) [1], and trastuzumab 
monoclonal antibody [2-4]. Benefits of CT were first demonstrated in the 1970s with the 
CMF (cyclophosphamide, methotrexate, fluorouracil) regimen, then with the addition of 
anthracycline in the 1980s [5]. During the last decade, 4-6 cycles of anthracycline plus 
cyclophosphamide +/- fluorouracil have been used as “standard” adjuvant regimens for 
axillary lymph node-negative (N-) and positive (N+) patients [6]. Taxanes were 
introduced in the anthracycline-based regimens for N+ patients in the late 2000s [7]. 
The factors used in routine to predict the metastatic risk and the probability of 
therapeutic response are insufficient to face the heterogeneous clinical behavior of 
breast cancer. In consequence, all N+ patients empirically receive regimens based on 
anthracyclines and taxanes without knowing if the tumor will be sensitive to this drug 
combination [8]. Taxanes are expensive, toxic, and the associated benefit is small (3 to 
7%) in term of 5-year survival [9-13], suggesting that a majority of patients do not benefit 
from the addition of taxane to anthracycline-based regimens. Thus, taxanes are not 
universally accepted as standard treatment [7], and an anthracycline-based regimen 
without taxane remains a valid option. Today, the choice of adjuvant cytotoxic regimen is 
based more upon the risks of relapse and toxicity, patient’s comorbidities, and 
physician’s experience, than upon the probability of efficiency. Given the increasing 
availability of new drugs, orienting patients towards the most likely beneficial regimen is 
even more crucial. This challenge supposes to better assess the metastatic risk after a 
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given CT regimen. Today, no biological factor predictive for efficiency of anthracycline-
based adjuvant CT has been validated and introduced in routine use [14,15].  
Several retrospective studies have shown the prognostic potential of gene 
expression profiling in breast cancer [16]. Relevant subtypes of disease have been 
identified [17,18]. Multigene signatures associated with survival have been reported in 
different settings: without any adjuvant systemic therapy [19-28], and after adjuvant HT 
[29-33]. Two of them are being tested in prospective randomized genomics-based trials 
launched in N- patients [34]: “Microarray in Node-Negative Disease May Avoid 
Chemotherapy Trial” (MINDACT), and “Trial Assigning Individualized Options for 
Treatment (Rx)” (TAILORx), the aim of which is to decrease the unnecessary indications 
of adjuvant CT. Some of these prognostic tests are commercialized and proposed to 
help the management of N- patients [35]. By contrast, few data are available on the 
signatures specifically associated with clinical outcome after CT. Some studies 
analyzed the response to primary CT [36-44]. One reported a signature specific to the 
delivered regimens [40]. In the setting of adjuvant CT, the published series are relatively 
small [45-48] or heterogeneous regarding CT regimens [49,50]. 
In this study, we aimed at identifying a signature predictive of metastatic relapse 
after adjuvant anthracycline-based CT without taxane. Using DNA microarrays, we 
profiled a multicentric series of 595 breast carcinomas, including 498 from patients 
treated with such adjuvant regimen. To avoid overfitting often pointed out in microarray 
studies, the predictor was first identified in a learning set of 323 patients, then validated 
in an independent set of 175 patients treated for most of them in a multicentric 
prospective clinical trial [13]. 
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MATERIALS AND METHODS 
 
Breast tumor samples 
 
Tumor samples were obtained after initial surgery from 595 early breast cancer 
patients treated in several French institutions: Institut Paoli-Calmettes (IPC, n=243), 
Centre Léon Bérard (CLB, n=110), Institut Bergonié (IB, n=114), and PACS01 clinical 
trial (A arm, n=128). Immediately after surgery, samples had been dissected by 
pathologists and snap-frozen in liquid nitrogen for storing. 
Of these 595 tumors, 498 came from patients who had received adjuvant post-
operative CT and were used to identify and validate the expression signature 
associated with metastatic relapse (Table 1). All had received 5 to 6 cycles of 2
nd
 
generation adjuvant CT, including an anthracycline (doxorubicine or epirubicine) 
combined with cyclophosphamide and fluorouracil. None of them had received taxane or 
trastuzumab in adjuvant setting. Patients with hormone receptor-positive tumor received 
adjuvant HT according to standard guidelines of the moment. They included all “IPC” and 
“CLB patients”. The “IB samples”, initially profiled for another study, included 17 cases 
treated with CT. Poor prognosis criteria that determined delivery of CT included N+ 
status or age under 40 years, pathological tumor size greater than 20 mm, Scarff-
Bloom-Richardson (SBR) grade equal to 3, or negative estrogen receptor status (ER) 
as evaluated by immunohistochemistry (IHC). The validation series also included 128 
samples form N+ patients treated in the PACS01 trial, a multicentric prospective 
randomized trial promoted by a network of national cancer centres (FNCLCC), which 
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compared 6 FEC100 cycles (A arm) vs 3 FEC100 cycles followed by 3 docetaxel 
cycles (B arm) for the adjuvant treatment [13]. In the A arm, 128 frozen tumor samples 
coming from 17 French hospitals were available for profiling. Histoclinical 
characteristics and outcome of these patients did not differ from the entire trial cohort. 
Follow-up data were obtained for all patients at regular intervals. The median follow-up 
of the 498-patient series was 68 months. During this period, 129 patients experienced 
metastatic relapse and the 5-year metastasis-free survival (MFS) was 76%. The main 
characteristics of this series are listed in Table 2 (1
st
 and 2
nd
 columns). Before sending 
frozen samples to Ipsogen, all tumor sections were reviewed by pathologists in each 
centre. All contained a percentage of cancer cells superior to 60%. This study was 
approved by our local ethics committees, and all patients gave informed consent. 
 
Gene expression profiling and data analysis 
RNA extraction and gene expression profiling were done at Ipsogen (Marseille, 
France). Profiling was done with two different platforms: platform 1 used Ipsogen 
DiscoveryChip cDNA microarrays (Ipsogen, Marseille, France; 
http://www.ipsogen.com/) for 565 samples, and platform 2 used Affymetrix U133 Plus 
2.0 oligonucleotide chips for 30 samples from IPC. Platform 1 cDNA microarrays 
contained PCR products from a total of 9.040 Image and control clones. These 
microarrays were used as previously described [51-53]. After normalization, analysis 
was based on biologically and/or clinically relevant metagenes defined from supervised 
and unsupervised analyses. To prevent overfitting, the metagene-based predictor was 
identified in a learning set of 323 tumors out of the 498 samples treated with adjuvant 
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CT, and validated in the 175 remaining independent tumors. Experimental procedures 
and metagene-based data analysis are detailed in Supplementary Text. 
 
Statistical analyses 
Distributions of histoclinical factors were compared using the Chi-2 test. The 
primary end-point was the MFS, calculated from the date of diagnosis until the date of 
first distant metastasis. Data concerning patients without metastatic relapse at last 
follow-up were censored. Follow-up was calculated from the date of diagnosis to the 
time of last follow-up for censored patients. Survival curves were derived from Kaplan-
Meier estimates [54] and compared by log-rank test. The prognostic impact of the 
genomic predictor was assessed in multivariate analysis by the Cox proportional hazard 
models, which included all features with a 15% level of significance in univariate analysis 
[55]. Cox models were built using a variable stepwise selection procedure. We also 
compared the prognostic value of our genomic classifier with that of the clinical 
Nottingham Prognostic Index (NPI) classifier [56]. Classical NPI cut-offs were used: 
score inferior or equal to 3.4 for low-risk, score between 3.5 and 5.4 for intermediate-
risk, and score superior to 5.4 for high-risk. Survival rates and hazards ratios (HR) were 
calculated with their 95% confidence intervals (95%CI). Statistical tests were two-sided 
at the 5% level of significance.  
 
 
RESULTS 
 
Identification and selection of metagenes 
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To avoid complex steps of normalization between expression data generated 
from two different DNA microarray sources, this first part of the analysis was done from 
the data generated on platform 1 (565 samples). 
Identification of phenotypic signatures 
Supervised MaxT method identified five gene expression signatures associated 
with ER, PR, ERBB2, EGFR and Ki67 immunohistochemical (IHC) status of tumors, 
respectively. Results are summarized in Supplementary Table 1 (see 
Supplementary Table 2 for the complete gene lists). As expected, several genes 
previously associated with ER status were retrieved in the ER signature [45,57-59]: 
ESR1, GATA3, SCUBE2, TFF1, TFF3, and XBP1, overexpressed in the ER-positive 
samples, and STK6/AURKA, ENO1 and ITGB3, underexpressed. The ERBB2 
signature contained genes located in the 17q amplicon (ERBB2, GRB7, ITGB3, 
PPARPB, PECAM1 and STAT3) [51,58]. 
The robustness of each signature was verified in the remaining tumors 
(Supplementary Table 1), with accuracy of prediction ranging from 78% to 96%. From 
these five signatures, 10 gene subsets were defined (under- and over-ER, under- and 
over-PR, under- and over-ERBB2, under- and over-EGFR, and under- and over-Ki67), 
respectively composed by the genes positively and the genes negatively correlated with 
the phenotype. For example, the ER signature contained two subsets, “over-ER” and 
“under-ER”, which included genes respectively overexpressed and underexpressed in 
ER-positive tumors. Then, for each subset, the expression levels of the component 
genes were averaged, defining a total of 10 metagenes.  
Hierarchical clustering 
Global clustering of the 468 tumors treated with adjuvant CT (Figure 1A) sorted 
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two major classes of samples strongly correlated with the ER IHC status (Figure 1B): 
85% of samples were ER-positive in the left class vs 32% in the right class (p<0.0001, 
Chi-2 test). Most tumors were grade III in the right class and grade I in the left class 
(p<0.0001, Chi-2 test). More tumors were ERBB2-positive in the right class than in the 
left class (p<0.0001, Chi-2 test). No correlation existed between clustering and 
metastatic relapse.  
Clustering revealed clusters of co-expressed genes, some of which (Figure 1C) 
corresponding to defined biological processes or cell types [37,58,60]: the “luminal”, the 
"ERBB2”, and the "basal” clusters, and other clusters (“proliferation”, “stromal”, 
“immune” and “early response”). We selected 17 gene clusters that satisfied to the 
chosen selection criteria (node correlation ≥0.5 and minimum of 5 genes: see colored 
bars to the right of Figure 1A). Most of them were included in or were close to relevant 
above-cited gene clusters. For each subset, the corresponding metagene was 
computed as defined above. 
Selection of metagenes 
Twenty-seven gene subsets were thus defined: 10 from supervised analyses, and 
17 from clustering. To avoid redundancy of variables (metagenes) entered in the Cox 
model, a two-step selection was applied. In a first step, 5 of the 17 subsets defined by 
clustering, which corresponded to phenotypic signatures, were excluded (Figure 1A). In 
a second step, colinearity analysis applied to subsets defined from supervised analyses 
excluded over-ER, over-PR and under-ERBB2, which were highly correlated with under-
EGFR and together. Eventually, 19 metagenes were retained for building the predictor. 
 
Identification of a genomic predictor associated with metastatic relapse 
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Cox proportional hazards analysis was applied to these 19 metagenes entered 
as continuous variables (Supplementary Table 3) and to the 323 tumors of the 
learning set treated with adjuvant CT. Within this series, 98 patients developed 
metastatic relapse with a median time to relapse of 36 months, and 225 patients 
remained relapse-free with a median follow-up of 73 months. By univariate analysis, 
none of the metagenes was associated with MFS. By multivariate analysis, three 
metagenes (under-EGFR, under-PR and under-ER representing 189 genes/ESTs) were 
retained, suggesting a synergy between them. Genes/ESTs included in these three 
metagenes are listed in Supplementary Table 2. A “Risk Score” (RS) was computed 
as a linear combination of the three metagenes and calculated for each tumor as 
follows:  
RS = (-2.90 x “under-ER”) - (1.47 x “under-PR”) - (4.17 x “under-EGFR”)  
The RS ranged from -1.33 to 1.37, with a high score associated with poor 
outcome. The optimal cut-off was the 3
rd
 quartile (RS value=0.09). As expected, the 
predictor performed well in term of prognosis: the “good-prognosis group” (RS <0.09, 
242 patients, 60 metastatic relapses) had a 5-year MFS of 79%, while the “poor-
prognosis group” (RS >0.09, 81 patients, 38 metastatic relapses) had a 5-year MFS of 
52% (p<0.0001, log-rank test) (Figure 2A). The hazard ratio (HR) for metastatic relapse 
was 2.35 (95%CI [1.6-3.5]). The performances of this genomic predictor were 
compared with those of traditional individual prognostic features. As shown in Table 3, 
the genomic predictor was the most significant feature and remained significant in 
multivariate analysis, after adjustment for other features.  
 
Validation of the predictor and comparison with the NPI classifier 
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We next tested our genomic predictor in the validation set of 175 independent 
samples (145 profiled using platform 1 and 30 using Affymetrix). None of these samples 
had been used to define the predictor. Of this series, 31 patients displayed a metastatic 
relapse with a median time of 30 months, and 144 women remained without metastatic 
relapse after a median follow-up of 61 months. The same “Risk Score”, calculated for 
each patient, with the same threshold defined two groups in the same proportions as in 
the learning set (75% and 25% respectively). These groups strongly correlated with 
outcome, suggesting the robustness of the predictor: 14 metastatic relapses in the 43 
patients of the “poor-prognosis group” and only 17 in the 132 of the “good-prognosis 
group” (p=0.003, Chi-2 test; Figure 2B). The accuracy of prediction of relapse was 
74%. The respective 5-year MFS were 87% and 65% (p<0.001, log-rank test) with a HR 
of 3.18 (95%CI [1.6-6.5]). Respective MFS were 87% and 61% (p<0.001, log-rank test) 
with a HR of 3.87 (95%CI [1.6-9.0]) when applied only to the 128 patients of the 
prospective PACS01 trial.  
Univariate and multivariate analyses were applied to this independent validation 
set (Table 3). Univariate analysis identified six factors as correlated with MFS (p<0.05, 
log-rank test): grade, number of positive axillary lymph nodes, pathological tumor size, 
ER and ERBB2 status, and the genomic predictor. In multivariate analysis, two factors 
remained significant, among which the predictor was the strongest one with an adjusted 
HR for metastasis of 4.5 for "poor-prognosis group" patients (95%CI [2.1-9.7]). 
We compared the prognostic performances of the genomic predictor and the NPI 
classifier in the validation set. NPI score could be calculated for 166 out of 175 samples, 
with 7 cases defined as low-risk, 85 as intermediate-risk and 74 as high-risk. For 
reasons of size, we merged the low-risk and the intermediate-risk cases to create a “not 
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high” risk group (92 cases) which was then compared to the high-risk group (74 cases). 
In univariate analysis, the NPI classifier was associated with MFS (Table 3). In 
multivariate analysis including the genomic and the NPI classifiers (Table 3) both 
remained significant with the genomic classifier showing the strongest HR (3.47 vs 
2.44). Analysis of unadjusted and adjusted HR for MFS in high- versus low-risk patients 
as defined by the two classifiers confirmed these data. Adjustment of the genomic 
predictor HR for the NPI classifier increased from 3.2 to 3.5. By contrast, the HR of the 
NPI classifier decreased after adjustment for the genomic predictor from 2.8 to 2.5. The 
NPI low-risk patients (N=92, 90% 5-year MFS) were separated by the genomic 
predictor in “good-“ and “poor-prognosis groups” with respective 5-year MFS of 93% 
and 75% (p=0.02, log-rank test; HR=4, 95%CI [1.1-15.2]). The same was true for the 
NPI high-risk patients (N=74; 76% 5-year MFS) who were separated in “good-“ and 
“poor-prognosis groups” with respective 5-year MFS of 85% and 57% (p=0.009, log-
rank test; HR=3.2, 95%CI [1.3-8.2]). By contrast, the “good-prognosis group” defined by 
the genomic predictor (N=123, 90% 5-year MFS) was separated by the NPI classifier in 
“not high” and high risk groups with not significantly different 5-year MFS: 93% and 85% 
respectively (p=0.07, log-rank test; HR=2.7, 95%CI [0.9-8.3]). Similarly, he “poor-
prognosis” patients defined by the genomic predictor (N=43; 65% 5-year MFS) were 
separated by the NPI classifier in two groups with not significantly different 5-year MFS 
(p=0.15, log-rank test; HR=2.3, 95%CI [0.7-7.3]). 
 
Genomic predictor-based classification and histoclinical correlations 
We then assessed the correlation of our predictor-based classification with 
histoclinical factors in the 498 pooled cases (Table 2). With a median follow-up of 68 
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months after diagnosis, the 5-year MFS was 76% (Supplementary Figure 1A). The 
factors associated with our classification (p<0.05, Chi-2 test) were axillary lymph node 
status, SBR grade, ER, PR and Ki67 status. As expected, a strong correlation existed 
with clinical outcome: 52 of the 124 patients (42%) assigned to the “poor-prognosis 
group” displayed metastatic relapse, vs only 77 of the 374 (21%) assigned to the “good-
prognosis group” (p<0.0001, Chi-2 test). With similar follow-up, the respective 5-year 
MFS were 56% and 82% (p<0.0001, log-rank test; Supplementary Figure 1B). The 
HR for metastasis was 2.5 (95%CI [1.8-3.6]). 
The genomic predictor kept its prognostic value in subgroups of patients. For N+ 
patients (Supplementary Figure 1C), the 5-year MFS were 80% in the "good-
prognosis group" and 54% in the "poor-prognosis group" (p<0.0001, log-rank test). The 
same was true for N- patients, with respective 5-year MFS of 95% vs 64% (p=0.005, 
log-rank test; Supplementary Figure 1D). Interestingly, the 5-year MFS in the “good-
prognosis” N+ patients (80%) was better than in the “poor-prognosis” N- patients (64%, 
p<0.05; log-rank test). Similarly, in the ER-positive group, the 5-year MFS were 83% 
and 52% respectively (p<0.0001, log-rank test). The same trend was observed for the 
ER-negative group with respective 5-year MFS of 78% and 61% (p=0.12, log-rank test). 
Unequal performance of a predictive multigene signature has been reported previously 
by others [33,61]. Histological grade is another important feature of breast cancer. Five-
year MFS was 81% in the “good-prognosis group” and 49% in the “poor-prognosis 
group” within the grade II tumors (p<0.001, log-rank test). The same was true for the 
grade III tumors with respective 5-year MFS of 77% and 57% (p=0.002, log-rank test). 
These results showed that our predictor adds prognostic information beyond that 
provided by the major prognostic factors. As expected, uni- and multivariate analyses 
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performed in this whole set of 498 tumors gave the same results than in the validation 
set (data not shown). 
 
 
DISCUSSION 
 
Refining the assessment of the metastatic risk after a given CT regimen and the 
decision regarding what regimen to use is one of the two major priorities for 
translational breast cancer research [62]. Using DNA microarrays, we profiled a 
multicentric series of 595 breast cancers, including 498 cases treated with adjuvant 
anthracycline-based CT without taxane. To our knowledge, this is the largest expression 
profiling study that specifically addresses the issue of survival prediction in breast 
cancer after a specific regimen of adjuvant therapy.  
In patients treated with anthracycline-based CT without taxane, our predictor 
identified a “good-prognosis group” (~75% of patients) with 82% 5-year MFS and a 
“poor-prognosis group” (~25% of patients) with 56% 5-year MFS. The strength of our 
results relies on several points: the large samples series, representative of the 
population treated with adjuvant CT, the homogeneity of adjuvant CT, the use of a 
learning set and a totally independent validation set, the profiling on two different 
technological platforms, and the similar performances of our multigene predictor in the 
learning and the validation sets. We first identified a genomic predictor of MFS after CT 
in a retrospective multicentric series of 323 samples: the HR for metastatic relapse was 
2.35 between the two predictor-based patients groups, with an overall predictive 
accuracy of 77%. The robustness of the predictor was confirmed in the validation set of 
 17 
175 similarly treated samples with 74% of accurate prediction and a resulting HR of 
3.18. Importantly, 73% of patients from the validation set were treated in the reference 
arm of a prospective multicentric clinical trial [13] and with heterogeneous conditions of 
sample acquisition and handling across 17 different hospitals. Two different microarray 
platforms were used for the validation set. All these potential sources of heterogeneity 
did not alter the performance of our predictor. The predictor outperformed the individual 
current prognostic factors in multivariate analysis, both in the learning and the validation 
sets, as well as the NPI prognostic classifier, and added independent prognostic 
information.  
Our predictor could help tailor the adjuvant CT regimens in patients candidate to 
CT. In the “good-prognosis group”, sensitivity to anthracyclines and/or weak metastatic 
propensity may explain the favorable survival. As compared with historical data of 
untreated patients the benefit of adjuvant CT appears substantial [63,64], suggesting 
that these patients remain candidates for adjuvant anthracycline-based CT, with or 
without taxane. Conversely and as compared with data of untreated patients [63,64], the 
benefit of anthracycline-based CT without taxane in the “poor-prognosis group” appears 
weak A different CT regimen (without anthrcayclines) or the testing of new drugs in 
clinical trials should be considered in this group.  
In the adjuvant setting, the onset of metastasis depends on several factors, 
including sensitivity to systemic therapy but also intrinsic disease aggressiveness. At 
the biological level, our predictor translates a complex interaction between factors that 
govern natural history of disease and chemosensitivity. Whether the included genes are 
causative or predictive of the phenotype or reflect another associated phenomenon 
remains to be explored. Several genes have a known biological or clinical relevance in 
breast cancer, such as ESR1, BCL2, TP53, PLAT and MAPT. Although individual 
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genes may have functional relevance, the coordinated expression of several gene 
families and cell processes is likely to be the most important determinant of outcome. 
This was well evidenced by the statistical significance of the three predictor metagenes 
that we observed in multivariate analysis, but not in univariate analysis. The under-ER 
and under-PR metagenes, which overall scored high in “poor-prognosis tumors”, 
comprised genes associated with proliferation (AURKA, CDK4, CDKL5, cyclin genes, 
ENO1), stroma (ITGB3, proteases MMP7,15, CTSC, PLAT), immune response 
(IGHG1, interleukin receptors, CD300C) and basal phenotype (S100A6,A8, SFRP1, 
LAMB1). Conversely, the under-EGFR metagene, which overall scored high in “good-
prognosis tumors”, was rather associated with the luminal phenotype (ESR1, KRT18, 
GATA3, XBP1, TFF1-3, SCUBE2). Some genes and/or pathways included in our 
predictor might be used as targets for specific therapies. 
 
 
CONCLUSIONS  
 
Our predictor is a first step toward optimal selection of the most likely beneficial 
adjuvant CT regimen. Additional steps are required regarding its validation. The first 
one will be to confirm prospectively the MFS of the two groups of patients. We have 
recently launched a prospective study in “good-prognosis” N+ patients [65]. If validated, 
this predictor would allow moving away from the “one shoe fits all” strategy used in 
oncology for many years [66] and from the ongoing “therapeutical escalation”. Such an 
issue is complementary to that addressed for N- patients in the ongoing MINDACT and 
TAILORx trials [34]. Finally, because our predictor is also relevant in N- early breast 
 19 
cancer, it might be useful for tailoring the adjuvant CT regimens in those patients defined 
as candidates for CT.  
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FIGURE LEGENDS  
 
Figure 1. Hierarchical clustering of tumors treated with adjuvant chemotherapy. 
A/ Hierarchical clustering of 468 samples and 2.261 filtered clones, based on 
expression data generated with Ipsogen microarrays. Each row represents a gene and 
each column a sample. The expression level of each gene in each sample is relative to 
its median abundance across the samples and is depicted according to the color scale 
shown. Red and green indicate expression levels respectively above and below the 
median. Colored branches in the dendrogram of genes and colored bars in the left 
column to the right of the matrix indicate the locations of gene clusters of interest 
zoomed in C. Black and grey bars in the right column to the right of the matrix indicate 
the location of gene clusters selected to define metagenes from clustering: bars with an 
* show the 12 clusters entered in the predictor building (from top to bottom, metagenes 
141, 171, 144, 51, 448, 1001, 27, 310, 240, 48, 187, and 66). Other bars correspond 
(from top to bottom) to metagenes 678, 875, 242, 8, and 9 not retained to build the 
predictor. B/ Dendrogram and histoclinical features of samples. Top, two large groups 
of samples (left and right) are evidenced and delimited by the orange vertical line. 
Bottom, some relevant features of samples are represented according to a color ladder 
(unavailable, oblique feature): ER, PR, ERBB2 IHC status (negative, white; positive, 
black), SBR grade (I, white; II, grey; III, black), and metastatic relapse during follow-up 
(no, white; yes, black). C/ Expanded view of selected gene clusters named from top to 
bottom: luminal/ER (dark blue bar), proliferation (dark grey), early response (dark 
green), stromal (orange), ERBB2-related (pink), basal (red), immune (light green). 
Some genes (EntrezGene symbol) included in each cluster are listed. 
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Figure 2: Classification of tumors treated with adjuvant chemotherapy based on 
the genomic predictor and survival. 
Correlation between the classification of 498 tumors based on the genomic predictor 
and the occurrence of metastatic relapse in the learning set of samples (A) and in the 
validation set (B). Left, cross-table; Right, Kaplan-Meier metastasis-free survival curves. 
HR means hazard ratio for metastasis in the “poor-prognosis group” as compared to the 
“good-prognosis group”. 
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Table 1: Samples from 498 patients treated with adjuvant chemotherapy and 
used for identification and validation of the genomic predictor. 
 
Table 2: Histoclinical characteristics of 498 patients treated with adjuvant 
chemotherapy, according to the membership to the "good-prognosis" or the 
"poor-prognosis group" as defined using the genomic predictor. 
 
Table 3: Cox proportional-hazards univariate and multivariate analyses in 
metastasis-free survival in the learning and the validation sets of patients 
treated with adjuvant chemotherapy. 
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SUPPLEMENTARY FILES 
 
Supplementary text 
 
Supplementary Figure 1: Kaplan-Meier MFS for patients treated with adjuvant 
anthracycline-based chemotherapy. A/ MFS for all 498 patients. B-D/ MFS in the 
"good-prognosis group” or the "poor-prognosis group” defined using the genomic 
predictor; B/, MFS for all 498 patients; C/ MFS for 417 patients with N+ cancer; D/, MFS 
for 80 patients with N- cancer. HR means hazard ratio for metastasis in the “poor-
prognosis group” as compared to the “good-prognosis group”. 
 
Supplementary Table 1: Description and performance of phenotypic gene 
expression signatures identified by supervised analysis (MaxT method).  
 
Supplementary Table 2: Phenotypic gene expression signatures associated 
with ER, PR, ERBB2, EGFR and Ki67 identified by supervised MaxT method. 
 
Supplementary Table 3: Univariate-multivariate Cox analysis of 19 metagenes 
for metastasis-free survival (MFS) in 323 patients from the learning set.  
 
Supplementary Table 4: Histoclinical data of the 595 tumors profiled. 
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Table 1: Samples from 498 patients treated with adjuvant chemotherapy and 
used for identification and validation of the genomic predictor. 
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Institution 
No. of 
samples 
Microarray 
platform 
Use in this 
study 
Paoli-Calmettes 213 
Ipsogen 
DiscoveryChip 
Learning 
set Léon Bérard 110 
Bergonié 17 
Validation 
set 
PACS01, A arm  128 
Paoli-Calmettes 30 
Affymetrix  
U133 Plus 2.0 
 
 
 
Table 2: Histoclinical characteristics of 498 patients treated with adjuvant 
chemotherapy, according to the membership to the "good-prognosis" or the 
"poor-prognosis group" as defined using the genomic predictor 
 
Characteristics  
All patients 
(N=498) 
Good-prognosis 
group* 
(N=374) 
 
Poor-prognosis 
group* 
(N=124) 
 
p-value† 
No. of patients  
(percent of evaluated cases) 
 
Age, years 
     ≤50 
     ≥50 
 
250 (50) 
248 (50) 
 
192 (51) 
182 (49) 
 
58 (47) 
66 (53) 
0.4 
 
Menopause 
     no 
     yes 
 
283 (58) 
206 (42) 
 
216 (59) 
152 (41) 
 
57 (55) 
54 (45) 
0.5 
Lymph node metastasis 
     0 
     1-3 
     >3 
 
80 (16) 
255 (51) 
162 (33) 
 
48 (13) 
199 (53) 
126 (34) 
 
32 (26) 
56 (45) 
36 (29) 
0.0004 
 
Pathological tumor size 
     pT1 
     pT2 
     pT3 
 
139 (22) 
282 (63) 
71 (15) 
 
110 (30) 
208 (56) 
51 (14) 
 
29 (24) 
74 (60) 
20 (16) 
0.4 
 
SBR grade 
     I 
     II 
     III 
 
65 (14) 
213 (45) 
208 (41) 
 
60 (17) 
173 (48) 
130 (36) 
 
5 (4) 
40 (33) 
78 (63) 
<0.0001 
ER status§ 
     negative 
     positive 
 
145 (28) 
326 (72) 
 
80 (22) 
279 (78) 
 
65 (58) 
47 (42) 
<0.0001 
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PR status§ 
     negative 
     positive 
 
182 (36) 
291 (64) 
 
113 (31) 
246 (69) 
 
69 (61) 
45 (39) 
<0.0001 
ERBB2 status§ 
     negative 
     positive 
 
331 (85) 
54 (15) 
 
251 (85) 
43 (15) 
 
80 (88) 
11 (12) 
0.6 
EGFR status§ 
     negative 
     positive 
 
114 (77) 
35 (23) 
 
89 (77) 
27 (23) 
 
25 (76) 
8 (24) 
1 
Ki67 status§ 
     negative 
     positive 
 
62 (50) 
77 (50) 
 
57 (53) 
50 (47) 
 
5 (16) 
27 (84) 
0.0002 
Follow-up††, months 
     median (range) 
 
68 (1, 175) 
 
68 (1, 175) 
 
68 (7, 155) 
1 
 
5-year MFS 
     % [95%CI] 
 
76 [71.7 - 79.7] 
 
82 [77.8 - 86.1] 
 
56.[47.5 - 66.4] 
<0.0001 
*, as defined using the genomic predictor; 
†, p-values were calculated using the Chi-2 test for the comparison of numbers of 
patients, using the log-rank test for the comparison of metastasis-free survival (MFS), 
and using the Student T-test for the comparison of follow-up; 
§, protein expression status was measured in each center using IHC on whole sections 
using the following positivity cut-offs: ≥10% for ER (estrogen receptor), PR 
(progesterone receptor), and EGFR (epidermal growth factor receptor), ≥20% for Ki67 
and 3+ for ERBB2 (HercepTest)  
††calculated, for the 369 patients who did not experience metastatic relapse, from the 
date of diagnosis to the time of last follow-up; 
Note: SBR, Scarff-Bloom-Richardson; CI, confidence interval. 
 
 
Table 3: Cox proportional-hazards univariate and multivariate analyses in 
metastasis-free survival in the learning and the validation sets of patients 
treated with adjuvant chemotherapy. 
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Univariate analysis  Multivariate analysis 
Sample set Variable HR [95%CI] p-value  HR [95%CI] p-value 
Learning set Genomic group - Poor-prognosis vs Good-prognosis 2.3 [1.6-3.5] <0.0001  2.3 [1.47-3.49] 0.00021 
 Age - >50 vs ≤50 1.2 [0.8-1.8] 0.40  --- --- 
 Menopause - yes vs no 1.1 [0.7-1.6] 0.68  --- --- 
 Lymph node metastasis - >3 vs ≤3 1.5 [1-2.3] 0.046  1.6 [1.02-2.39] 0.041 
 Pathological tumor size- pT2-3 vs pT1 1.1 [0.7-1.7] 0.79  --- --- 
 SBR Grade - 2-3 vs 1 2.4 [1.1-5.1] 0.025  NS NS 
 ER status - pos vs neg 0.9 [0.6-1.4] 0.55  --- --- 
 PR status - pos vs neg 0.7 [0.4-1] 0.05  NS NS 
 ERBB2 status - pos vs neg 1 [0.5-2] 0.98  --- --- 
       
Validation set Genomic group - Poor-prognosis vs Good-prognosis 3.2 [1.6–6.5] 0.0008  4.5 [2.12–9.71] <0.0001 
 Age - >50 vs ≤50 1.2 [0.6-2.3] 0.68  --- --- 
 Menopause - yes vs no 1.1 [0.5-2.4] 0.76  --- --- 
 Lymph node metastasis - >3 vs ≤3 3 [1.5-6.1] 0.0017  2.8 [1.30-5.93] 0.0085 
 Pathological tumor size- pT2-3 vs pT1 2.4 [1-6] 0.048  NS NS 
 SBR Grade - 2-3 vs 1 --- 0.0138  NS NS 
 ER status - pos vs neg 0.5 [0.2-1] 0.046  NS NS 
 PR status - pos vs neg 0.7 [0.4-1.5] 0.37  --- --- 
 ERBB2 status - pos vs neg 2.8 [1.2-6.2] 0.0099  NS NS 
              
Validation set Genomic group - Poor-prognosis vs Good-prognosis 3.2 [1.6-6.5] 0.0008  3.5 [1.61-7.45] 0.001 
 NPI classifier – high-risk vs not high risk 2.8 [1.3-6.3] 0.0076  2.4 [1.08-5.47] 0.03 
